| Migraine Disorders
Emgality vs Nurtec ODT
Side-by-side clinical, coverage, and cost comparison for migraine disorders.Deep comparison between: Emgality vs Nurtec Odt with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.Safety signalsNurtec Odt has a higher rate of injection site reactions vs Emgality based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Nurtec Odt but not Emgality, including UnitedHealthcare
Sign up to reveal the full AI analysis
Category
Emgality
Nurtec Odt
At A Glance
SC injection
Monthly
CGRP antagonist
Oral
As needed or every other day
CGRP receptor antagonist
Indications
- Migraine Disorders
- Cluster Headache
- Migraine Disorders
- Episodic migraine
Dosing
Migraine Disorders 240 mg loading dose (two consecutive SC injections of 120 mg each) once, followed by 120 mg SC monthly.
Cluster Headache 300 mg (three consecutive SC injections of 100 mg each) at the onset of the cluster period, then monthly until the end of the cluster period.
Migraine Disorders 75 mg orally as needed; maximum 75 mg per 24-hour period; safety of more than 18 doses in a 30-day period has not been established; may be taken with or without food.
Episodic migraine 75 mg orally every other day, with or without food.
Contraindications
- Serious hypersensitivity to galcanezumab-gnlm or any of the excipients
- History of hypersensitivity reaction to rimegepant, NURTEC ODT, or any of its components, including anaphylaxis and delayed serious hypersensitivity
Adverse Reactions
Most common (>=2%) Injection site reactions
Serious Hypersensitivity reactions, hypertension, Raynaud's phenomenon
Postmarketing Anaphylaxis, angioedema, rash, hypertension, Raynaud's phenomenon
Most common Nausea, abdominal pain/dyspepsia
Serious Hypersensitivity including dyspnea and severe rash
Postmarketing Hypersensitivity (anaphylaxis), hypertension, Raynaud's phenomenon
Pharmacology
Galcanezumab-gnlm is a humanized monoclonal antibody that binds to calcitonin gene-related peptide (CGRP) ligand and blocks its binding to the receptor; it is not metabolized by cytochrome P450 enzymes, making interactions with CYP substrates, inducers, or inhibitors unlikely.
Rimegepant is a calcitonin gene-related peptide (CGRP) receptor antagonist; it is an orally administered small molecule that blocks the CGRP receptor implicated in migraine pathophysiology, indicated for both acute and preventive treatment.
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
Emgality
- Covered on 5 commercial plans
- PA (11/12) · Step Therapy (10/12) · Qty limit (11/12)
Nurtec Odt
- Covered on 5 commercial plans
- PA (12/12) · Step Therapy (12/12) · Qty limit (12/12)
UnitedHealthcare
Emgality
- Covered on 4 commercial plans
- PA (8/8) · Step Therapy (7/8) · Qty limit (8/8)
Nurtec Odt
- Covered on 4 commercial plans
- PA (6/8) · Step Therapy (6/8) · Qty limit (6/8)
Humana
Emgality
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (1/3) · Qty limit (3/3)
Nurtec Odt
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (3/3) · Qty limit (3/3)
Coverage data sourced from MMIT. Updated monthly.
Savings
Cost estimate not availableHealthWell: Migraine
Commercial or private insurance
Medicare, Medicaid, VA, TRICARE
Cost estimate not availableHealthWell: Migraine
Commercial or private insurance
Medicare, Medicaid, VA, TRICARE
Compare Other Drugs
Let us handle your prior authsJust enter your patient's info and we'll:
- Verify eligibility with the payer.
- Pull the right PA forms directly from the payer.
- Submit, track & send live updates to your dashboard.
Free to start · HIPAA compliant
Next Steps for Your Patient
EmgalityView full Emgality profile
Nurtec OdtView full Nurtec Odt profile
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.